OncoCyte Corporation (NASDAQ: OCX) reported Q2 EPS of ($1.03), $0.27 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $362.5 thousand.

For earnings history and earnings-related data on OncoCyte Corporation (OCX) click here.